Literature DB >> 24772261

Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion.

Xavier Freixa1, Rut Andrea1, Victoria Martín-Yuste1, Diego Fernández-Rodríguez1, Salvatore Brugaletta1, Mónica Masotti1, Manel Sabaté1.   

Abstract

Cardioembolic events are one of the most feared complications in patients with non-valvular atrial fibrillation (NVAF) and a formal contraindication to oral anticoagulation (OAC). The present case report describes a case of massive peripheral embolism after an implantable cardiac defibrillator (ICD) shock in a patient with NVAF and a formal contraindication to OAC due to previous intracranial hemorrhage. In order to reduce the risk of future cardioembolic events, the patient underwent percutaneous left atrial appendage (LAA) occlusion. A 25 mm Amplatzer™ Amulet was implanted and the patient was discharged the following day without complications. The potential risk of thrombus dislodgement after an electrical shock in patients with NVAF and no anticoagulation constitutes a particular scenario that might be associated with an additional cardioembolic risk. Although LAA occlusion is a relatively new technique, its usage is rapidly expanding worldwide and constitutes a very valid alternative for patients with NVAF and a formal contraindication to OAC.

Entities:  

Keywords:  Atrial fibrillation; Defibrillator; Implantable cardiac defibrillator; Left atrial appendage

Year:  2014        PMID: 24772261      PMCID: PMC3999341          DOI: 10.4330/wjc.v6.i4.213

Source DB:  PubMed          Journal:  World J Cardiol


  6 in total

Review 1.  Why do patients with atrial fibrillation not receive warfarin?

Authors:  T J Bungard; W A Ghali; K K Teo; F A McAlister; R T Tsuyuki
Journal:  Arch Intern Med       Date:  2000-01-10

2.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

3.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation.

Authors:  C J Bjerkelund; O M Orning
Journal:  Am J Cardiol       Date:  1969-02       Impact factor: 2.778

4.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

5.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

6.  Stroke severity in atrial fibrillation. The Framingham Study.

Authors:  H J Lin; P A Wolf; M Kelly-Hayes; A S Beiser; C S Kase; E J Benjamin; R B D'Agostino
Journal:  Stroke       Date:  1996-10       Impact factor: 7.914

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.